Kristen O’Brien is an accomplished healthcare executive with a deep understanding of regulatory advocacy and healthcare policy efforts.
Kristen offers a strong background and a keen eye for solutions to barriers and challenges impacting healthcare clients. With more than 10 years of experience, her work focuses on implementing new laws through the rulemaking process, as well as working with relevant agency officials to develop and improve agency guidance.
Kristen recently served as Principal of the Health Industry Policy and Regulatory Practice Group at a law and lobbying firm where she provided representation for hospital systems, physician practices, medical device companies, digital health companies and trade associations. She has extensive experience in providing analysis and counsel related to government healthcare payment programs under Medicare and Medicaid. She also has extensive knowledge of navigating the Centers for Medicare & Medicaid Services (CMS), the Office of the National Coordinator for Health Information Technology (ONC) and others.
Previously, Kristen provided legislative and regulatory legal analysis as a senior attorney for the American Medical Association. Additionally, Kristen served on the staff of former Senator Max Baucus (D-MT), focusing on health and environmental issues, as well as financial reform.
No Surprises Act Update: The TMA III Decision
CMS Releases FY 2024 IPPS Final Rule
CMS Releases CY 2024 Physician Fee Schedule Proposed Rule
End-Stage Renal Disease Prospective Payment System CY 2024 Rule Update
Site Neutral Payment: Top 10 Services Likely to Be Impacted By Proposed Legislation
CMS Withdraws COVID-19 Vaccination Mandate, Enhances Focus on Quality Measures
CMS Unwinds Waivers as the COVID-19 PHE Comes to an End
Federal Government to Wind Down Vaccination Mandates
CMS Releases FY 2024 IPPS Proposed Update
CMS Updates CY 2023 Physician Conversion Factor to $33.8872
Consolidated Appropriations Act, 2023: Health Provisions
Assessing the CY 2023 Medicare PFS Impact on Multi-Specialty Group Practices
CMS Releases CY 2023 End-Stage Renal Disease Prospective Payment System Final Rule
CMS Finalizes CY 2023 Physician Fee Schedule Rule
CMS Releases FY 2023 IPPS Final Rule
CMS Releases CY 2023 Physician Fee Schedule Proposed Rule
CMS Releases CY 2023 End-Stage Renal Disease Prospective Payment System Proposed Rule
CMS Releases FY 2023 IPPS Proposed Update
SUPREME COURT OKS CMS VACCINE MANDATE BUT BLOCKS OSHA RULE
Key Takeaways from the 2nd Part of FY 2022 IPPS Final Rule
End-Stage Renal Disease Prospective Payment System CY 2022 Rule Update
CMS ISSUES COVID-19 VACCINATION INTERIM FINAL RULE FOR HEALTHCARE FACILITIES
CMS Innovation Center Strategy Refresh: Policy Update
Interim Final Rule with comment (IFR) to Surprise Billing; Part II
CMS Releases FY 2022 IPPS Final Rule
Health Policy Breakroom - Ep 75 No Surprises Billing Act 1 day ago1 day ...
Requirements Related to Surprise Billing; Part I: Policy Update
Leveraging Real World Data and Real World Evidence: How the FDA and ...
President’s Fiscal Year 2022 Budget: What You Need to Know
Buoyed by Federal Covid Aid, Big Hospital Chains Buy Up Competitors
Health Policy Breakroom Ep. 67 - FY 2022 IPPS Proposed Rule
CMS Releases FY 2022 IPPS Proposed Update
TPNIES – Leveraging Lessons Learned From NTAP
American Rescue Plan Act of 2021: Key Healthcare Provisions
The First 100 Days: Biden's Healthcare Outlook
Summary of Key Health Provisions in the Consolidated Appropriations Act, 2021
The Vaccine – Understanding What’s Next
UPDATED: CMS Finalizes 10% Payment Cut, Expands Telehealth Services in 2021 Physician Fee Schedule
Show MoreDo not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.
